Literature DB >> 28527634

Low penetration of caspofungin into cerebrospinal fluid following intravenous administration of standard doses.

Volker Strenger1, Fedja Farowski2, Carsten Müller3, Nora Hofer4, Hans Jürgen Dornbusch4, Daniela Sperl4, Herwig Lackner4, Martin Benesch4, Christian Urban4.   

Abstract

The kinetics of caspofungin (CAS) in cerebrospinal fluid (CSF) following intravenous (i.v.) administration has been studied exclusively in animal models. Human data are missing so far. In this study, 13 CSF samples were obtained at different time points following i.v. infusion of CAS in ten paediatric haemato-/oncological patients (age range 1.0-14.2 years, median 8.6 years) without signs of central nervous system (CNS) infection (n = 10 samples) or with infectious meningitis (n = 3 samples). Serum samples were obtained concurrently. Liquid chromatography-tandem mass spectrometry was used for CAS quantification. Whilst CAS serum levels were in the expected range, varying between 0.6 and 20.3 µg/mL (median 7.0 µg/mL), 11 of 13 CSF levels were below the limit of detection of 0.084 µg/mL at 3.0-48.0 h (median 23.3 h) following i.v. infusion. Only two (of three) levels in patients with bacterial meningitis were above the limit of detection (0.3 µg/mL and 0.09 µg/mL, respectively). These results indicate the low capacity of CAS to penetrate into the CNS even in inflamed meninges. Monotherapy with standard doses of CAS appears not to be suitable for treatment of fungal CNS infections.
Copyright © 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Blood–brain barrier; CNS infection; Caspofungin; Echinocandin; Invasive fungal infection

Mesh:

Substances:

Year:  2017        PMID: 28527634     DOI: 10.1016/j.ijantimicag.2017.02.024

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  5 in total

Review 1.  Administration and Dosing of Systemic Antifungal Agents in Pediatric Patients.

Authors:  Kevin J Downes; Brian T Fisher; Nicole R Zane
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

2.  Anidulafungin and Micafungin Concentrations in Cerebrospinal Fluid and in Cerebral Cortex.

Authors:  Jana Marx; René Welte; Tiziana Gasperetti; Patrizia Moser; Ronny Beer; Martin Ortler; Martina Jeske; Ramona Stern; Andreas Pomaroli; Michael Joannidis; Romuald Bellmann
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

3.  Invasive mucormycosis during treatment for acute lymphoblastic leukaemia-successful management of two life-threatening diseases.

Authors:  Andreas Trobisch; R Marterer; G Gorkiewicz; S Flaschberger; H Lackner; M Seidel; D Sperl; A Karastaneva; B Kohlmaier; M Egger; C Urban; M Benesch; V Strenger
Journal:  Support Care Cancer       Date:  2019-08-14       Impact factor: 3.603

4.  Antifungal Drugs: Special Problems Treating Central Nervous System Infections.

Authors:  Elizabeth Dodds Ashley
Journal:  J Fungi (Basel)       Date:  2019-10-11

5.  Caspofungin induces the release of Ca2+ ions from internal stores by activating ryanodine receptor-dependent pathways in human tracheal epithelial cells.

Authors:  Sabrina Müller; Christian Koch; Sebastian Weiterer; Markus A Weigand; Michael Sander; Michael Henrich
Journal:  Sci Rep       Date:  2020-07-16       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.